Liposomes are a promising drug delivery system, owing to their biocompatibility and ability to efficiently encapsulate and protect a wide range of molecules for medical applications. Active targeting of the liposomes is typically performed by surface modification, which enables delivery of the liposomes to a specific target tissue. Tumor cells are characterized by high glucose demand and high metabolic activity, because of the increased requirement of energy to feed uncontrolled proliferation. Taking advantage of the increased glucose uptake by cancer cells, we developed a glucose-labeled liposome, which is tumor-targeted - both by recognition of over-expressed glucose transporters on tumor cells, and by the unique characteristics of tumor vasculature that allow greater accumulation of nanoparticles. In this study, glucosecoated liposome uptake was evaluated in different types of cancer cells, both quantitatively and qualitatively. We found that liposomes with glucose coating were preferentially uptaken by cancer cell lines with high metabolic activity, compared to liposomes without glucose coating. Moreover, cell lines with high metabolic activity exhibited higher uptake of liposomes with glucose coating, as compared to cell lines with low metabolic activity and to non-cancerous cell lines.
|Title of host publication||Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIX|
|Editors||Dror Fixler, Ewa M. Goldys, Sebastian Wachsmann-Hogiu|
|State||Published - 2022|
|Event||Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIX 2022 - Virtual, Online|
Duration: 20 Feb 2022 → 24 Feb 2022
|Name||Progress in Biomedical Optics and Imaging - Proceedings of SPIE|
|Conference||Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIX 2022|
|Period||20/02/22 → 24/02/22|
Bibliographical noteFunding Information:
This work was supported by Ze’ev Jabotinsky doctoral scholarship granted to Chen Tzror-Azankot by the Ministry of Science, Technology & Space, Israel.
Copyright © 2022 SPIE.